{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:51:34Z","timestamp":1792612294023,"version":"4.5.0"},"reference-count":178,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Metabolites"],"abstract":"<jats:p>Inflammatory bowel diseases (IBDs) and metabolic disorders are increasingly recognized as interconnected conditions that frequently coexist and influence each other\u2019s clinical course. Accumulating evidence indicates that patients with IBD face a substantial burden of obesity, metabolic syndrome, metabolic dysfunction-associated steatotic liver disease, osteoporosis, and type 2 diabetes. These associations appear to be driven by shared and interacting mechanisms, including intestinal barrier disruption, gut microbiota dysbiosis, chronic systemic inflammation, and adipose tissue-mediated immunometabolic pathways. Metabolic comorbidities may worsen IBD activity, reduce response to therapy, increase complications, and contribute to higher health care utilization. Conversely, intestinal inflammation and commonly used treatments, particularly corticosteroids, can adversely affect glucose metabolism, lipid metabolism, body composition and bone homeostasis. Advanced therapies have demonstrated variable metabolic effects, some of which may be beneficial through suppression of systemic inflammation. Recognition of these bidirectional interactions highlights the importance of routine metabolic screening and integrated, multidisciplinary management. Lifestyle interventions, nutritional optimization and individualized therapeutic strategies represent central parts of comprehensive management.<\/jats:p>","DOI":"10.3390\/metabo16030181","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T08:58:45Z","timestamp":1773046725000},"page":"181","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Metabolic Disorders and Inflammatory Bowel Diseases: Unraveling Shared Pathways and Clinical Interactions"],"prefix":"10.3390","volume":"16","author":[{"given":"Fotios","family":"Fousekis","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, University Hospital of Ioannina, 45500 Ioannina, Greece"},{"name":"Medical Department 2, Academic Teaching Hospital F\u00fcrth, Friedrich-Alexander Universit\u00e4t Erlangen-N\u00fcrnberg, 90766 F\u00fcrth, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afroditi","family":"Lamprou","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, University Hospital of Ioannina, 45500 Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Saridi","sequence":"additional","affiliation":[{"name":"Department of Nursing, University of Thessaly, 41500 Larissa, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8579-0627","authenticated-orcid":false,"given":"Ioanna Nefeli","family":"Mastorogianni","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, University Hospital of Ioannina, 45500 Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Mpakogiannis","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, University Hospital of Ioannina, 45500 Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios D.","family":"Lianos","sequence":"additional","affiliation":[{"name":"Department of Surgery, University Hospital of Ioannina, 45500 Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos H.","family":"Katsanos","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, University Hospital of Ioannina, 45500 Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMra0804647","article-title":"Inflammatory bowel disease","volume":"361","author":"Abraham","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Saez, A., Herrero-Fernandez, B., Gomez-Bris, R., Sanchez-Martinez, H., and Gonzalez-Granado, J.M. (2023). Pathophysiology of Inflammatory Bowel Disease: Innate Immune System. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021526"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Haneishi, Y., Furuya, Y., Hasegawa, M., Picarelli, A., Rossi, M., and Miyamoto, J. (2023). Inflammatory Bowel Diseases and Gut Microbiota. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24043817"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1056\/NEJMra2002697","article-title":"Pathophysiology of Inflammatory Bowel Diseases","volume":"383","author":"Chang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/ecco-jcc\/jjv232","article-title":"Prevalence and Characteristics of Extra-intestinal Manifestations in a Large Cohort of Greek Patients with Inflammatory Bowel Disease","volume":"10","author":"Karmiris","year":"2016","journal-title":"J. Crohns Colitis"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/s41586-025-08940-0","article-title":"Global evolution of inflammatory bowel disease across epidemiologic stages","volume":"642","author":"Hracs","year":"2025","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"ii3","DOI":"10.1093\/ecco-jcc\/jjae082","article-title":"Epidemiology of Inflammatory Bowel Disease across the Ages in the Era of Advanced Therapies","volume":"18","author":"Caron","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1053\/j.gastro.2023.07.003","article-title":"Incidence, Prevalence, and Racial and Ethnic Distribution of Inflammatory Bowel Disease in the United States","volume":"165","author":"Lewis","year":"2023","journal-title":"Gastroenterology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"307","DOI":"10.5009\/gnl240316","article-title":"Metabolic Disorders and Inflammatory Bowel Diseases","volume":"19","author":"Hyun","year":"2025","journal-title":"Gut Liver"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/s41575-022-00658-y","article-title":"The metabolic nature of inflammatory bowel diseases","volume":"19","author":"Adolph","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"6789","DOI":"10.3390\/ijerph20186789","article-title":"Metabolic Diseases-A Challenge for Public Health in the 21st Century","volume":"20","year":"2023","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/jimd.12348","article-title":"An international classification of inherited metabolic disorders (ICIMD)","volume":"44","author":"Ferreira","year":"2021","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Hamooya, B.M., Siame, L., Muchaili, L., Masenga, S.K., and Kirabo, A. (2025). Metabolic syndrome: Epidemiology, mechanisms, and current therapeutic approaches. Front. Nutr., 12.","DOI":"10.3389\/fnut.2025.1661603"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"108","DOI":"10.7570\/jomes24004","article-title":"Effects of Metabolic Dysfunction-Associated Steatotic Liver Disease on Bone Density and Fragility Fractures: Associations and Mechanisms","volume":"33","author":"Khanmohammadi","year":"2024","journal-title":"J. Obes. Metab. Syndr."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Hyun, C.K. (2021). Molecular and Pathophysiological Links between Metabolic Disorders and Inflammatory Bowel Diseases. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22179139"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Casas-Deza, D., Garcia-Lopez, S., Bernal-Monterde, V., Polo-Cuadro, C., Yague-Caballero, C., and Arbones-Mainar, J.M. (2025). Obesity-Mediated Inflammation and Its Influence on Inflammatory Bowel Disease: Pathophysiology, Clinical Impact, and Therapeutic Implications. Biomolecules, 15.","DOI":"10.3390\/biom15081185"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1136\/gutjnl-2024-331914","article-title":"Heavy arch: From inflammatory bowel diseases to metabolic disorders","volume":"73","author":"Adolph","year":"2024","journal-title":"Gut"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e074659","DOI":"10.1136\/bmjopen-2023-074659","article-title":"Prevalence of metabolic syndrome in patients with inflammatory bowel disease: A systematic review and meta-analysis","volume":"14","author":"Shen","year":"2024","journal-title":"BMJ Open"},{"key":"ref_20","first-page":"350","article-title":"Prevalence and Associated Factors of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Disease: An Updated Global Systematic Review and Meta-Analysis of over 1.5 Million Individuals","volume":"32","author":"Ghodous","year":"2025","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/apt.16879","article-title":"Meta-analysis: Prevalence of, and risk factors for, non-alcoholic fatty liver disease in patients with inflammatory bowel disease","volume":"55","author":"Zamani","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.cgh.2021.06.049","article-title":"Obesity is Associated with Increased Risk of Crohn\u2019s disease, but not Ulcerative Colitis: A Pooled Analysis of Five Prospective Cohort Studies","volume":"20","author":"Chan","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1111\/obr.12875","article-title":"Body mass index and risk of inflammatory bowel disease: A systematic review and dose-response meta-analysis of cohort studies of over a million participants","volume":"20","author":"Rahmani","year":"2019","journal-title":"Obes. Rev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s41043-025-00946-8","article-title":"Prevalence of osteoporosis in patients with inflammatory bowel disease: A systematic review and meta-analysis","volume":"44","author":"Emadian","year":"2025","journal-title":"J. Health Popul. Nutr."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Huang, S., Pan, Y., Liu, Z., Liang, Y., Qin, S., and Jiang, H. (2025). Individual components and cumulative burden of metabolic syndrome are associated with higher disease activity and adverse outcomes in Crohn\u2019s disease. Front. Med., 12.","DOI":"10.3389\/fmed.2025.1721566"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Njeim, R., Moussa, E., Sohail, A., Wei, C., Abou Yassine, A., and Deeb, L. (2026). Metabolic Comorbidities and Hospital Outcomes in Patients with Inflammatory Bowel Disease: A Nationwide Analysis. J. Clin. Gastroenterol.","DOI":"10.1097\/MCG.0000000000002333"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/MEG.0000000000003067","article-title":"Prevalence and risk factors of metabolic dysfunction-associated steatotic liver disease in patients with inflammatory bowel disease","volume":"38","author":"Tamimi","year":"2026","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"109035","DOI":"10.4254\/wjh.v17.i9.109035","article-title":"From gut to liver: Exploring the relationship between inflammatory bowel disease and metabolic dysfunction-associated steatotic liver disease","volume":"17","author":"Lopes","year":"2025","journal-title":"World J. Hepatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"7528","DOI":"10.3748\/wjg.v26.i47.7528","article-title":"Prevalence and associated factors of obesity in inflammatory bowel disease: A case-control study","volume":"26","author":"Losurdo","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"630","DOI":"10.14309\/ajg.0000000000000197","article-title":"Impact of Obesity on Disease Activity and Patient-Reported Outcomes Measurement Information System (PROMIS) in Inflammatory Bowel Diseases","volume":"114","author":"Jain","year":"2019","journal-title":"Am. J. Gastroenterol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s11894-022-00840-x","article-title":"Impact of Obesity on Inflammatory Bowel Disease","volume":"24","author":"Khakoo","year":"2022","journal-title":"Curr. Gastroenterol. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1007\/s00198-018-4586-6","article-title":"Risk of fracture and low bone mineral density in adults with inflammatory bowel diseases. A systematic literature review with meta-analysis","volume":"29","author":"Szafors","year":"2018","journal-title":"Osteoporos. Int."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1093\/ecco-jcc\/jjaa019","article-title":"Incidence, Risk Factors and Evaluation of Osteoporosis in Patients with Inflammatory Bowel Disease: A Danish Population-Based Inception Cohort with 10 Years of Follow-Up","volume":"14","author":"Lo","year":"2020","journal-title":"J. Crohns Colitis"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.57187\/s.3407","article-title":"Bone health in patients with inflammatory bowel disease","volume":"154","author":"Kreienbuehl","year":"2024","journal-title":"Swiss Med. Wkly."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1007\/s10620-020-06439-4","article-title":"Comorbid Diabetes in Inflammatory Bowel Disease Predicts Adverse Disease-Related Outcomes and Infectious Complications","volume":"66","author":"Kumar","year":"2021","journal-title":"Dig. Dis. Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.dld.2022.08.017","article-title":"Influence of diabetes mellitus on inflammatory bowel disease course and treatment outcomes. A systematic review with meta-analysis","volume":"55","author":"Fuschillo","year":"2023","journal-title":"Dig. Liver Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1093\/ibd\/izz305","article-title":"Disease Characteristics and Severity in Patients with Inflammatory Bowel Disease with Coexistent Diabetes Mellitus","volume":"26","author":"Din","year":"2020","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.3748\/wjg.v20.i13.3507","article-title":"Glucose intolerance and diabetes mellitus in ulcerative colitis: Pathogenetic and therapeutic implications","volume":"20","author":"Maconi","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/s41467-025-67268-5","article-title":"Worldwide trends in metabolic syndrome from 2000 to 2023: A systematic review and modelling analysis","volume":"17","author":"Noubiap","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1007\/s00535-010-0247-z","article-title":"Prevalence of metabolic syndrome is comparable between inflammatory bowel disease patients and the general population","volume":"45","author":"Nagahori","year":"2010","journal-title":"J. Gastroenterol."},{"key":"ref_41","first-page":"618","article-title":"Epidemiology of metabolic syndrome in patients with inflammatory bowel disease: A population-level cohort study from the United States","volume":"38","author":"Desai","year":"2025","journal-title":"Ann. Gastroenterol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S2468-1253(19)30173-6","article-title":"Comorbidities in inflammatory bowel disease: A call for action","volume":"4","author":"Argollo","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra2412865","article-title":"Metabolic Dysfunction-Associated Steatotic Liver Disease","volume":"393","author":"Targher","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1093\/ibd\/izad175","article-title":"Inflammatory Bowel Disease Is an Independent Risk Factor for Metabolic Dysfunction-Associated Steatotic Liver Disease in Lean Individuals","volume":"30","author":"Callau","year":"2024","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1093\/ibd\/izaf098","article-title":"Unravelling the Relationship Between Obesity and Inflammatory Bowel Disease","volume":"31","author":"Sun","year":"2025","journal-title":"Inflamm. Bowel. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1177\/2050640620954556","article-title":"Impact of obesity on disease activity and disease outcome in inflammatory bowel disease: Results from the Swiss inflammatory bowel disease cohort","volume":"8","author":"Greuter","year":"2020","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00384-014-2051-3","article-title":"The effect of body weight on the severity and clinical course of ulcerative colitis","volume":"30","author":"Leifeld","year":"2015","journal-title":"Int. J. Color. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/nutrit\/nuab028","article-title":"A systematic review and meta-analysis of prospective studies on obesity and risk of inflammatory bowel disease","volume":"80","author":"Milajerdi","year":"2022","journal-title":"Nutr. Rev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/1759720X16670154","article-title":"Bone modeling and remodeling: Potential as therapeutic targets for the treatment of osteoporosis","volume":"8","author":"Langdahl","year":"2016","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/S0140-6736(22)01655-5","article-title":"Type 2 diabetes","volume":"400","author":"Ahmad","year":"2022","journal-title":"Lancet"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Xu, J., Zhang, Q., Wang, Z., Liu, S., Zhu, S., Zhang, S., and Wu, S. (2025). Bidirectional Association of Type 2 Diabetes Mellitus and Inflammatory Bowel Diseases: A Large-scale Prospective Cohort Study. J. Clin. Gastroenterol.","DOI":"10.1097\/MCG.0000000000002264"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.cgh.2019.07.052","article-title":"Inflammatory Bowel Diseases Increase Risk of Type 2 Diabetes in a Nationwide Cohort Study","volume":"18","author":"Jess","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Tang, L.T., Feng, L., Cao, H.Y., Shi, R., Luo, B.B., Zhang, Y.B., Liu, Y.M., Zhang, J., and Li, S.Y. (2024). Investigation of the causal relationship between inflammatory bowel disease and type 2 diabetes mellitus: A Mendelian randomization study. Front. Genet., 15.","DOI":"10.3389\/fgene.2024.1325401"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Xiao, X., Wu, X., Yi, L., You, F., Li, X., and Xiao, C. (2024). Causal linkage between type 2 diabetes mellitus and inflammatory bowel disease: An integrated Mendelian randomization study and bioinformatics analysis. Front. Endocrinol., 15.","DOI":"10.3389\/fendo.2024.1275699"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00592-024-02254-9","article-title":"Causal effects of inflammatory bowel disease on risk of type 2 diabetes: A two-sample multivariable Mendelian randomization study","volume":"61","author":"Niu","year":"2024","journal-title":"Acta Diabetol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S2468-1253(24)00390-X","article-title":"The intestinal barrier: A pivotal role in health, inflammation, and cancer","volume":"10","author":"Neurath","year":"2025","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Di Tommaso, N., Gasbarrini, A., and Ponziani, F.R. (2021). Intestinal Barrier in Human Health and Disease. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph182312836"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1093\/ibd\/izaf225","article-title":"Intestinal Barrier Dysfunction in Inflammatory Bowel Disease: Pathophysiology to Precision Therapeutics","volume":"31","author":"Selvakumar","year":"2025","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"C1723","DOI":"10.1152\/ajpcell.00704.2025","article-title":"From gut to blood: Barrier dysfunction as a driver of systemic low-grade inflammation in cardiometabolic disease","volume":"329","author":"Nagele","year":"2025","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1203\/01.PDR.0000163397.53466.0F","article-title":"Monocyte toll-like receptor 4 expression and LPS-induced cytokine production increase during gestational aging","volume":"58","author":"Sadeghi","year":"2005","journal-title":"Pediatr. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1074\/jbc.M113.521161","article-title":"Lipopolysaccharide activates Toll-like receptor 4 (TLR4)-mediated NF-kappaB signaling pathway and proinflammatory response in human pericytes","volume":"289","author":"Compte","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"15648","DOI":"10.1038\/s41598-018-33928-4","article-title":"Diet induced obesity is independent of metabolic endotoxemia and TLR4 signalling, but markedly increases hypothalamic expression of the acute phase protein, SerpinA3N","volume":"8","author":"Dalby","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Park, S.J., Garcia Diaz, J., Um, E., and Hahn, Y.S. (2023). Major roles of kupffer cells and macrophages in NAFLD development. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1150118"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Sultan, S., El-Mowafy, M., Elgaml, A., Ahmed, T.A.E., Hassan, H., and Mottawea, W. (2021). Metabolic Influences of Gut Microbiota Dysbiosis on Inflammatory Bowel Disease. Front. Physiol., 12.","DOI":"10.3389\/fphys.2021.715506"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Sharma, B., Agriantonis, G., Twelker, K., Ebelle, D., Kiernan, S., Siddiqui, M., Soni, A., Cheerasarn, S., Simon, W., and Jiang, W. (2025). Gut Microbiota Serves as a Crucial Independent Biomarker in Inflammatory Bowel Disease (IBD). Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26062503"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1136\/gutjnl-2013-304833","article-title":"A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis","volume":"63","author":"Machiels","year":"2014","journal-title":"Gut"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1093\/ecco-jcc\/jjad064","article-title":"Transepithelial Barrier Dysfunction Drives Microbiota Dysbiosis to Initiate Epithelial Clock-driven Inflammation","volume":"17","author":"Pai","year":"2023","journal-title":"J. Crohns Colitis"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Qin, Q., Yan, S., Yang, Y., Chen, J., Li, T., Gao, X., Yan, H., Wang, Y., Wang, J., and Wang, S. (2021). A Metagenome-Wide Association Study of the Gut Microbiome and Metabolic Syndrome. Front. Microbiol., 12.","DOI":"10.3389\/fmicb.2021.682721"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"152352","DOI":"10.1016\/j.bbrc.2025.152352","article-title":"TMAO regulates OTUB1-mediated SLC7A11 stability to promote NAFLD progression","volume":"778","author":"Zhong","year":"2025","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/ajcn\/nqac074","article-title":"Gut microbiota-derived metabolite trimethylamine-N-oxide and multiple health outcomes: An umbrella review and updated meta-analysis","volume":"116","author":"Li","year":"2022","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Clooney, A.G., Fouhy, F., Sleator, R.D., A, O.D., Stanton, C., Cotter, P.D., and Claesson, M.J. (2016). Comparing Apples and Oranges?: Next Generation Sequencing and Its Impact on Microbiome Analysis. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0148028"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Mayorga, L., Noguera Segura, A., Campderros, L., Pons-Tarin, M., Soler, Z., Vega-Abellaneda, S., Serrano-Gomez, G., Herrera-deGuise, C., Robles-Alonso, V., and Borruel, N. (2026). Distinct microbial mediators link diet to inflammation in Crohn\u2019s disease and ulcerative colitis. Gut.","DOI":"10.1136\/gutjnl-2025-337480"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s40259-025-00739-9","article-title":"Bidirectional Interplay Between IBD Therapies and the Gut Microbiota: A Pharmacomicrobiomic Approach to Personalized Treatment","volume":"39","author":"Lazarevic","year":"2025","journal-title":"BioDrugs"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1093\/cvr\/cvx108","article-title":"The role of infiltrating immune cells in dysfunctional adipose tissue","volume":"113","author":"Guzik","year":"2017","journal-title":"Cardiovasc. Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e13724","DOI":"10.1111\/obr.13724","article-title":"Inflammation-mediated metabolic regulation in adipose tissue","volume":"25","author":"Xu","year":"2024","journal-title":"Obes. Rev."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/imr.12858","article-title":"Immunometabolism: From basic mechanisms to translation","volume":"295","author":"Makowski","year":"2020","journal-title":"Immunol. Rev."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Karaskova, E., Velganova-Veghova, M., Geryk, M., Foltenova, H., Kucerova, V., and Karasek, D. (2021). Role of Adipose Tissue in Inflammatory Bowel Disease. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22084226"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/s41590-023-01479-0","article-title":"Macrophage function in adipose tissue homeostasis and metabolic inflammation","volume":"24","author":"Chavakis","year":"2023","journal-title":"Nat. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/MIB.0000000000000209","article-title":"Metabolic inflammation in inflammatory bowel disease: Crosstalk between adipose tissue and bowel","volume":"21","author":"Goncalves","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/mnfr.200700050","article-title":"Leptin, adiponectin, resistin, and ghrelin--implications for inflammatory bowel disease","volume":"52","author":"Karmiris","year":"2008","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1136\/gut.2006.117382","article-title":"Gut, inflammation and osteoporosis: Basic and clinical concepts","volume":"57","author":"Tilg","year":"2008","journal-title":"Gut"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1136\/gutjnl-2014-306947","article-title":"Bone marrow Th17 TNFalpha cells induce osteoclast differentiation, and link bone destruction to IBD","volume":"64","author":"Ciucci","year":"2015","journal-title":"Gut"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1136\/gut.2004.044370","article-title":"The RANKL\/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss","volume":"54","author":"Moschen","year":"2005","journal-title":"Gut"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/jbmr.3027","article-title":"Inflammatory Bowel Disease in a Rodent Model Alters Osteocyte Protein Levels Controlling Bone Turnover","volume":"32","author":"Metzger","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1002\/jbmr.3759","article-title":"Attenuation of NF-kappaB in Intestinal Epithelial Cells Is Sufficient to Mitigate the Bone Loss Comorbidity of Experimental Mouse Colitis","volume":"34","author":"Ke","year":"2019","journal-title":"J. Bone Miner. Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"102672","DOI":"10.1016\/j.autrev.2020.102672","article-title":"Mucosal vitamin D signaling in inflammatory bowel disease","volume":"19","author":"Kellermann","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ajpath.2023.02.004","article-title":"Vitamin D and Microbiome: Molecular Interaction in Inflammatory Bowel Disease Pathogenesis","volume":"193","author":"Aggeletopoulou","year":"2023","journal-title":"Am. J. Pathol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Wark, G., Kaakoush, N.O., Samocha-Bonet, D., Ghaly, S., and Danta, M. (2024). Dietary Determinants of Metabolic and Gut Microbial Health in Patients with Inflammatory Bowel Disease. Nutrients, 16.","DOI":"10.3390\/nu16193233"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"100219","DOI":"10.1016\/j.advnut.2024.100219","article-title":"Diet, Food, and Nutritional Exposures and Inflammatory Bowel Disease or Progression of Disease: An Umbrella Review","volume":"15","author":"Christensen","year":"2024","journal-title":"Adv. Nutr."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Konjar, S., Benedik, E., Sestan, M., Veldhoen, M., and Zupanic, A. (2025). Systems biology to unravel Western diet-associated triggers in inflammatory bowel disease. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1621334"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Sureda, A., Bibiloni, M.D.M., Julibert, A., Bouzas, C., Argelich, E., Llompart, I., Pons, A., and Tur, J.A. (2018). Adherence to the Mediterranean Diet and Inflammatory Markers. Nutrients, 10.","DOI":"10.3390\/nu10010062"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Perrone, P., and D\u2019Angelo, S. (2025). Gut Microbiota Modulation Through Mediterranean Diet Foods: Implications for Human Health. Nutrients, 17.","DOI":"10.3390\/nu17060948"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1053\/j.gastro.2013.07.050","article-title":"A prospective study of long-term intake of dietary fiber and risk of Crohn\u2019s disease and ulcerative colitis","volume":"145","author":"Ananthakrishnan","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1016\/j.tjnut.2023.06.013","article-title":"Higher Fiber Intake is Associated with Reduced Risk of Related Surgery among Individuals with Inflammatory Bowel Disease in a Prospective Cohort Study","volume":"153","author":"Deng","year":"2023","journal-title":"J. Nutr."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"6296","DOI":"10.3748\/wjg.v22.i27.6296","article-title":"Environmental risk factors for inflammatory bowel diseases: Evidence based literature review","volume":"22","author":"Abegunde","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1136\/gutjnl-2025-334922","article-title":"Smoking affects gut immune system of patients with inflammatory bowel diseases by modulating metabolomic profiles and mucosal microbiota","volume":"75","author":"Miyauchi","year":"2025","journal-title":"Gut"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Gui, X., Yang, Z., and Li, M.D. (2021). Effect of Cigarette Smoke on Gut Microbiota: State of Knowledge. Front. Physiol., 12.","DOI":"10.3389\/fphys.2021.673341"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1053\/j.gastro.2019.04.016","article-title":"Environmental Risk Factors for Inflammatory Bowel Diseases: An Umbrella Review of Meta-analyses","volume":"157","author":"Piovani","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Rio, P., Gasbarrini, A., Gambassi, G., and Cianci, R. (2024). Pollutants, microbiota and immune system: Frenemies within the gut. Front. Public Health, 12.","DOI":"10.3389\/fpubh.2024.1285186"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.cell.2019.08.010","article-title":"Antibiotics-Driven Gut Microbiome Perturbation Alters Immunity to Vaccines in Humans","volume":"178","author":"Hagan","year":"2019","journal-title":"Cell"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e1260","DOI":"10.1002\/mbo3.1260","article-title":"Impact of antibiotics on the human microbiome and consequences for host health","volume":"11","author":"Patangia","year":"2022","journal-title":"Microbiologyopen"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"He, Z., Sun, Y., Huang, H., Fu, T., Yuan, S., Larsson, S.C., Wolk, A., Ludvigsson, J.F., Wang, X., and Li, X. (Clin. Gastroenterol. Hepatol., 2025). Circulating Metabolite Signatures Linking Physical Activity to Inflammatory Bowel Disease Risk and Interactions with Genetic Susceptibility, Clin. Gastroenterol. Hepatol., in press.","DOI":"10.1016\/j.cgh.2025.11.013"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Xia, S., Zhang, J., Zhang, Z., Wang, X., Ye, D., and Fang, X. (2025). Physical activity, sedentary behavior and risk of inflammatory bowel disease: A prospective cohort study in the UK Biobank. BMC Public Health, 25.","DOI":"10.1186\/s12889-025-25647-z"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1053\/j.gastro.2025.01.224","article-title":"Exercise, the Gut Microbiome and Gastrointestinal Diseases: Therapeutic Impact and Molecular Mechanisms","volume":"169","author":"Hawley","year":"2025","journal-title":"Gastroenterology"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"3831972","DOI":"10.1155\/2017\/3831972","article-title":"Exercise Modifies the Gut Microbiota with Positive Health Effects","volume":"2017","author":"Monda","year":"2017","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Leal, L.G., Lopes, M.A., and Batista, M.L. (2018). Physical Exercise-Induced Myokines and Muscle-Adipose Tissue Crosstalk: A Review of Current Knowledge and the Implications for Health and Metabolic Diseases. Front. Physiol., 9.","DOI":"10.3389\/fphys.2018.01307"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Edwardson, C.L., Gorely, T., Davies, M.J., Gray, L.J., Khunti, K., Wilmot, E.G., Yates, T., and Biddle, S.J. (2012). Association of sedentary behaviour with metabolic syndrome: A meta-analysis. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0034916"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"311","DOI":"10.14309\/ajg.0000000000001584","article-title":"Objectively Measured Physical Activity Is Inversely Associated with Nonalcoholic Fatty Liver Disease: The Rotterdam Study","volume":"117","author":"Hofman","year":"2022","journal-title":"Am. J. Gastroenterol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"f6633","DOI":"10.1136\/bmj.f6633","article-title":"Physical activity and risk of inflammatory bowel disease: Prospective study from the Nurses' Health Study cohorts","volume":"347","author":"Khalili","year":"2013","journal-title":"BMJ"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Mavropoulou, E., Mechie, N.C., Knoop, R., Petzold, G., Ellenrieder, V., Kunsch, S., Pilavakis, Y., and Amanzada, A. (2020). Association of serum interleukin-6 and soluble interleukin-2-receptor levels with disease activity status in patients with inflammatory bowel disease: A prospective observational study. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0233811"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1055\/s-0034-1374587","article-title":"Systemic metabolic signaling in acute and chronic gastrointestinal inflammation of inflammatory bowel diseases","volume":"46","author":"Karrasch","year":"2014","journal-title":"Horm. Metab. Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1002\/iub.2293","article-title":"Serum levels of C1q\/TNF-related protein-3 in inflammatory bowel disease patients and its inverse association with inflammatory cytokines and insulin resistance","volume":"72","author":"Mohamadinarab","year":"2020","journal-title":"IUBMB Life"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.2147\/TCRM.S140618","article-title":"Are adipocytokines inflammatory or metabolic mediators in patients with inflammatory bowel disease?","volume":"13","author":"Kahraman","year":"2017","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/00054725-200606000-00005","article-title":"Profiling adipocytokine secretion from creeping fat in Crohn\u2019s disease","volume":"12","author":"Paul","year":"2006","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.nut.2008.07.020","article-title":"Circulating adipokines and the protective effects of hyperinsulinemia in inflammatory bowel disease","volume":"25","author":"Valentini","year":"2009","journal-title":"Nutrition"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Hwang, N., Kang, D., Shin, S.J., Yoon, B.K., Chun, J., Kim, J.W., and Fang, S. (2023). Creeping fat exhibits distinct Inflammation-specific adipogenic preadipocytes in Crohn\u2019s disease. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1198905"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11306-017-1311-y","article-title":"Alterations in Lipid, Amino Acid, and Energy Metabolism Distinguish Crohn\u2019s Disease from Ulcerative Colitis and Control Subjects by Serum Metabolomic Profiling","volume":"14","author":"Scoville","year":"2018","journal-title":"Metabolomics"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"jjaf082","DOI":"10.1093\/ecco-jcc\/jjaf082","article-title":"Distinct perturbances in metabolic pathways associate with disease progression in inflammatory bowel disease","volume":"19","author":"Bourgonje","year":"2025","journal-title":"J. Crohns Colitis"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"18699","DOI":"10.1038\/s41598-021-96942-z","article-title":"Exploring how microbiome signatures change across inflammatory bowel disease conditions and disease locations","volume":"11","author":"Amos","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"35039","DOI":"10.1038\/s41598-025-18106-7","article-title":"Associations of the intestinal microbiota with plasma bile acids and inflammation markers in Crohn\u2019s disease and ulcerative colitis","volume":"15","author":"Granstrom","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2527863","DOI":"10.1080\/19490976.2025.2527863","article-title":"Deciphering the microbiome-metabolome landscape of an inflammatory bowel disease inception cohort","volume":"17","author":"Radhakrishnan","year":"2025","journal-title":"Gut Microbes"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1038\/s41467-025-60233-2","article-title":"Metabolic modeling reveals a multi-level deregulation of host-microbiome metabolic networks in IBD","volume":"16","author":"Taubenheim","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e42791","DOI":"10.1097\/MD.0000000000042791","article-title":"Gut microbiota causally affects ulcerative colitis by potential mediation of plasma metabolites: A Mendelian randomization study","volume":"104","author":"Zhao","year":"2025","journal-title":"Medicine"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"e41710","DOI":"10.1097\/MD.0000000000041710","article-title":"The role of gut microbiota and plasma metabolites in ulcerative colitis: Insights from Mendelian randomization analysis","volume":"104","author":"Zheng","year":"2025","journal-title":"Medicine"},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Kou, R., Guo, Y., Qin, Z., Xu, X., Liu, Y., Wei, W., Chen, Y., Jian, Z., and Lan, B. (2025). Systemic dysregulation of the gut microenvironment plays a pivotal role in the onset and progression of inflammatory bowel disease. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1661386"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"e061476","DOI":"10.1136\/bmjopen-2022-061476","article-title":"Metabolic adverse events associated with systemic corticosteroid therapy-a systematic review and meta-analysis","volume":"12","author":"Kulkarni","year":"2022","journal-title":"BMJ Open"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1210\/clinem\/dgae250","article-title":"European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and Therapy of Glucocorticoid-induced Adrenal Insufficiency","volume":"109","author":"Beuschlein","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s40265-014-0282-9","article-title":"Systemic glucocorticoid therapy: A review of its metabolic and cardiovascular adverse events","volume":"74","author":"Fardet","year":"2014","journal-title":"Drugs"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"5628","DOI":"10.1007\/s10620-022-07488-7","article-title":"Weight and BMI Patterns in a Biologicals-Treated IBD Cohort","volume":"67","author":"Kaazan","year":"2022","journal-title":"Dig. Dis. Sci."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Shehab, M., Alali, A., Al-Hindawi, A., Alsayegh, A., Aldallal, U., Abdullah, I., Albaghli, A., Alrashed, F., Alfadhli, A., and Bessissow, T. (2022). Impact of tumor necrosis factor antagonist combination and anti-integrin therapies on body mass index in inflammatory bowel disease: A cross-sectional study. Front. Med., 9.","DOI":"10.3389\/fmed.2022.1045661"},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Boronat-Toscano, A., Monfort-Ferre, D., Menacho, M., Caro, A., Bosch, R., Espina, B., Algaba-Chueca, F., Saera-Vila, A., Molin\u00e9, A., and Marti, M. (2022). Anti-TNF Therapies Suppress Adipose Tissue Inflammation in Crohn\u2019s Disease. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231911170"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Burska, A.N., Sakthiswary, R., and Sattar, N. (2015). Effects of Tumour Necrosis Factor Antagonists on Insulin Sensitivity\/Resistance in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0128889"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"6712901","DOI":"10.1155\/2018\/6712901","article-title":"Favorable Effect of Anti-TNF Therapy on Insulin Sensitivity in Nonobese, Nondiabetic Patients with Inflammatory Bowel Disease","volume":"2018","author":"Paschou","year":"2018","journal-title":"Int. J. Endocrinol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2595874","DOI":"10.1080\/07853890.2025.2595874","article-title":"Efficacy and safety of IL-23p19 and IL-12\/23p40 inhibitors in moderate-to-severe Crohn\u2019s disease: A systematic review and network meta-analysis","volume":"57","author":"Kaneko","year":"2025","journal-title":"Ann. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(25)00681-6","article-title":"Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn\u2019s disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials","volume":"406","author":"Panaccione","year":"2025","journal-title":"Lancet"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(09)60140-9","article-title":"Ustekinumab, a human interleukin 12\/23 monoclonal antibody, for psoriatic arthritis: Randomised, double-blind, placebo-controlled, crossover trial","volume":"373","author":"Gottlieb","year":"2009","journal-title":"Lancet"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"e15793","DOI":"10.1111\/dth.15793","article-title":"Successful use of anti-IL-23 molecules in overweight-to-obese psoriatic patients: A multicentric retrospective study","volume":"35","author":"Ricceri","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/apt.16439","article-title":"The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme","volume":"54","author":"Farraye","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): A phase 2b\/3 double-blind, randomised, placebo-controlled trial","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: Results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.cgh.2019.04.059","article-title":"Tofacitinib Treatment Is Associated with Modest and Reversible Increases in Serum Lipids in Patients with Ulcerative Colitis","volume":"18","author":"Sands","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2455536","DOI":"10.1080\/07853890.2025.2455536","article-title":"Cardiovascular safety of Janus kinase inhibitors in inflammatory bowel disease: A systematic review and network meta-analysis","volume":"57","author":"Yang","year":"2025","journal-title":"Ann. Med."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s10067-021-06003-z","article-title":"Effect of JAK inhibitors on high- and low-density lipoprotein in patients with rheumatoid arthritis: A systematic review and network meta-analysis","volume":"41","author":"Li","year":"2022","journal-title":"Clin. Rheumatol."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Alsakarneh, S., Aburumman, R., Khraisat, F., Odeh, T., Hashash, J.G., Pardi, D.S., and Farraye, F.A. (2026). Major Adverse Cardiovascular Events and VTE in Patients with IBD Taking Anti-TNF versus JAK Inhibitors: A Multicenter Cohort Analysis. Dig. Dis. Sci.","DOI":"10.1007\/s10620-026-09729-5"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"jjaf106","DOI":"10.1093\/ecco-jcc\/jjaf107","article-title":"ECCO-ESGAR-ESP-IBUS Guideline on Diagnostics and Monitoring of Patients with Inflammatory Bowel Disease: Part 2","volume":"19","author":"Yanai","year":"2025","journal-title":"J. Crohns Colitis"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/apt.70485","article-title":"Systematic Review: Efficacy, Safety and Metabolic Outcomes of GLP-1 Receptor Agonists in Inflammatory Bowel Disease","volume":"63","author":"Maracle","year":"2026","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"jjaf167","DOI":"10.1093\/ecco-jcc\/jjaf167","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists in inflammatory bowel disease: Mechanisms, clinical implications, and therapeutic potential","volume":"19","author":"Colwill","year":"2025","journal-title":"J. Crohns Colitis"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1007\/s10620-025-08964-6","article-title":"Tolerability and Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Inflammatory Bowel Disease","volume":"70","author":"Clarke","year":"2025","journal-title":"Dig. Dis. Sci."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1093\/ibd\/izae147","article-title":"Metformin Is Associated with Improved Inflammatory Bowel Disease Outcomes in Patients with Type 2 Diabetes Mellitus: A Propensity-Matched Cohort Study","volume":"31","author":"Petrov","year":"2025","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Lee, S.Y., Lee, S.H., Yang, E.J., Kim, E.K., Kim, J.K., Shin, D.Y., and Cho, M.L. (2015). Metformin Ameliorates Inflammatory Bowel Disease by Suppression of the STAT3 Signaling Pathway and Regulation of the between Th17\/Treg Balance. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0135858"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/jgh.12435","article-title":"Anti-inflammatory mechanism of metformin and its effects in intestinal inflammation and colitis-associated colon cancer","volume":"29","author":"Koh","year":"2014","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/ibd.21348","article-title":"Thiazolidinedione use and ulcerative colitis-related flares: An exploratory analysis of administrative data","volume":"17","author":"Lund","year":"2011","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s00011-005-0002-8","article-title":"Attenuation of experimental colonic injury by thiazolidinedione agents","volume":"55","author":"Takaki","year":"2006","journal-title":"Inflamm. Res."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1007\/s00011-023-01796-y","article-title":"SGLT2 inhibitors prevent LPS-induced M1 macrophage polarization and alleviate inflammatory bowel disease by downregulating NHE1 expression","volume":"72","author":"Kim","year":"2023","journal-title":"Inflamm. Res."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41467-020-15983-6","article-title":"SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1007\/s11096-025-02026-7","article-title":"Comparative risks of inflammatory bowel disease in patients with type 2 diabetes mellitus treated with SGLT-2 inhibitors versus DPP-4 inhibitors: A real-world nationwide cohort study","volume":"47","author":"Yu","year":"2025","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1177\/1060028019827852","article-title":"Dipeptidyl Peptidase-4 Inhibitors and Inflammatory Bowel Disease Risk: A Meta-analysis","volume":"53","author":"Radel","year":"2019","journal-title":"Ann. Pharmacother."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/joim.70034","article-title":"Statin use for primary prevention of cardiovascular disease reduces the risk of incident IBD: A population-based cohort study","volume":"298","author":"Faye","year":"2025","journal-title":"J. Intern. Med."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/ecco-jcc\/jjaa235","article-title":"Association Between Statin Use and Inflammatory Bowel Diseases: Results from a Swedish, Nationwide, Population-based Case-control Study","volume":"15","author":"Lochhead","year":"2021","journal-title":"J. Crohns Colitis"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1093\/ibd\/izaf077","article-title":"Statin Use is Associated with a Less Severe Disease Course In Inflammatory Bowel Disease: A Nationwide Cohort Study 2006\u20132020","volume":"31","author":"Khalili","year":"2025","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/ibd\/izaf227","article-title":"Statin Use is Associated with Lower Odds of IBD-Related Surgery Among Patients with Moderate-to-Severe Inflammatory Bowel Disease","volume":"32","author":"Claytor","year":"2026","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1097\/MIB.0000000000000640","article-title":"Potential Immunomodulatory Effects of Statins in Inflammatory Bowel Disease","volume":"22","author":"Mehandru","year":"2016","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/fcp.12859","article-title":"Therapeutic effects and the impact of statins in the prevention of ulcerative colitis in preclinical models: A systematic review","volume":"37","author":"Vital","year":"2023","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Tao, H., Yu, Z., Dong, Y., Liu, L., Peng, L., and Chen, X. (2023). Lipids, lipid-lowering agents, and inflammatory bowel disease: A Mendelian randomization study. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1160312"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"100871","DOI":"10.1016\/j.jlr.2025.100871","article-title":"Lipid-lowering drug targets influence inflammatory bowel disease through gut microbiota and inflammatory cytokines","volume":"66","author":"Huang","year":"2025","journal-title":"J. Lipid Res."},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Wozniak, E., Broncel, M., Niedzielski, M., Wozniak, A., and Gorzelak-Pabis, P. (2023). The effect of lipid-lowering therapies on the pro-inflammatory and anti-inflammatory properties of vascular endothelial cells. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0280741"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/cvr\/cvae034","article-title":"Effect of lipid-lowering therapies on C-reactive protein levels: A comprehensive meta-analysis of randomized controlled trials","volume":"120","author":"Xie","year":"2024","journal-title":"Cardiovasc. Res."},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Capela, T.L., Silva, V.M., Freitas, M., Arieira, C., Goncalves, T.C., de Castro, F.D., Magalh\u00e3es, J., and Cotter, J. (2023). Identifying inflammatory bowel disease patients at risk of metabolic dysfunction-associated fatty liver disease: Usefulness of non-invasive steatosis predictive scores. BMC Gastroenterol., 23.","DOI":"10.1186\/s12876-023-02988-w"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/ibd\/izy200","article-title":"Screening for Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Diseases: A Cohort Study Using Transient Elastography","volume":"25","author":"Restellini","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Abenavoli, L., Scarlata, G.G.M., Borelli, M., Suraci, E., Marasco, R., Imeneo, M., Spagnuolo, R., and Luzza, F. (2025). Use of Metabolic Scores and Lipid Ratios to Predict Metabolic Dysfunction-Associated Steatotic Liver Disease Onset in Patients with Inflammatory Bowel Diseases. J. Clin. Med., 14.","DOI":"10.3390\/jcm14092973"},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Garcia-Mateo, S., Martinez-Dominguez, S.J., Gargallo-Puyuelo, C.J., Arroyo Villarino, M.T., Laredo De La Torre, V., Gallego, B., Alfambra, E., and Gomoll\u00f3n, F. (2023). Lifestyle Can Exert a Significant Impact on the Development of Metabolic Complications and Quality Life in Patients with Inflammatory Bowel Disease. Nutrients, 15.","DOI":"10.3390\/nu15183983"},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Jablonska, B., and Mrowiec, S. (2023). Nutritional Status and Its Detection in Patients with Inflammatory Bowel Diseases. Nutrients, 15.","DOI":"10.3390\/nu15081991"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/S2468-1253(22)00021-8","article-title":"Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: An International Organization for Study of Inflammatory Bowel Diseases consensus","volume":"7","author":"Ananthakrishnan","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1053\/j.gastro.2023.11.303","article-title":"AGA Clinical Practice Update on Diet and Nutritional Therapies in Patients with Inflammatory Bowel Disease: Expert Review","volume":"166","author":"Hashash","year":"2024","journal-title":"Gastroenterology"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/s41575-022-00619-5","article-title":"Dietary management of adults with IBD\u2014The emerging role of dietary therapy","volume":"19","author":"Fitzpatrick","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.nut.2018.11.028","article-title":"Current technologies in body composition assessment: Advantages and disadvantages","volume":"62","author":"Ceniccola","year":"2019","journal-title":"Nutrition"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/ecco-jcc\/jjz131","article-title":"Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review","volume":"14","author":"Colombel","year":"2020","journal-title":"J. Crohns Colitis"},{"key":"ref_178","first-page":"273","article-title":"Treat-to-Target in Inflammatory Bowel Disease: An Updated Survey of Treatment Strategies among Portuguese Gastroenterologists","volume":"32","author":"Fernandes","year":"2025","journal-title":"GE Port. J. Gastroenterol."}],"container-title":["Metabolites"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-1989\/16\/3\/181\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T09:27:40Z","timestamp":1773048460000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-1989\/16\/3\/181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":178,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["metabo16030181"],"URL":"https:\/\/doi.org\/10.3390\/metabo16030181","relation":{},"ISSN":["2218-1989"],"issn-type":[{"value":"2218-1989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]}}}